Què podem fer quan la colitis ulcerosa crònica contínua se'ns resisteix? I què podrem fer?

> Ingrid Ordás Hospital Clínic Barcelona

XXIII Congrés de la SCD

INTRODUCTION

♦ Chronic active UC is associated with:

- ♦ significant morbidity
- ♦ increased CCR risk
- ♦ disability, loss of productivity and increased cost
- ♦ Up to 18% of patients suffer chronic active disease
- ♦ 30% requiring colectomy at 10 years
- ♦ Management of these patients is challenging

Optimize Management

- ♦ Ensure maximal dose and correct topical formulation
- ♦ Combine oral and topical 5-ASA
- ♦ Appropriate CS tapering regime (prevent relapse)
- ♦ Adequate weight-based dose thiopurines
- ♦ Is there a role for methotrexate / leukocytapheresis?
- ♦ Anti-TNF Therapy: Drug Levels | Antidrug Antibodies

Principle of managing chronic unremitting UC

It should be standard practice to **confirm** disease activity **endoscopically before** considering **treatment escalation**

Adherence

♦ Adherence rates to mesalazine 60-70%

♦ Non-adherence is associated with


- ♦ increased risk of relapse
- \diamond reduced quality of life

♦ Risk factors for non-adherence

- ♦ male (67%vs 52%, p < 0.05)</p>
- ♦ single (68%vs 53%, p = 0.04)
- ♦ disease limited to the left side vs pancolitis (83%vs 51%, p < 0.01)</p>

Optimizing Therapy in Extensive Mild/Moderate UC Benefit of Combining Oral and Topical 5-ASA


Patients (%) improving



patients (%) with clinical improvement after 4 weeks of treatment

Marteau P et al. Gut 2005

Optimizing Therapy in Extensive Mild/Moderate UC Benefit of Combining Oral and Topical 5-ASA




5-ASA 4g/d + **PBO enema**

5-ASA 4g/d + 5-ASA 1g enema

patients (%) achieving clinical remission after 8 weeks of treatment

Patients (%) in remission

[Mesalazine] in rectal mucosa in UC patients treated with 5-ASA oral monotherapy vs. combined with 5-ASA enema



Pimpo MT et al. JCC 2010


Methotrexate in UC

♦ MTX proved efficacy in CD (25 mg/week i.m.)


 \diamond Data in UC is scarce

- $\diamond~$ One RCT has been negative with oral MTX
 - ♦ MTX 12,5 mg/week (N=30)
 - ♦ PBO (N=37)

Methotrexate in UC




Cumulative proportion of patients entering remission in both groups; MTX group (....), PBO (---)



Monthly steroid dose throughout the study (**■**MTX **•**PBO)

	Placebo group	Methotrexate group	P value
Completed the 9		_	
months of study	25	23	0.411
Dropouts	9 (0.5, 1, 2, 2, 2,		
	3, 3, 5, 6)	2 (1, 7)	0.052
Treatment failure	2 (3, 3)	3 (3, 5, 8)	0.476
Withdrawal because of			
side effects	1 (0.5)	2 (2, 5)	0.465
Total	37	30	


Table 2. Follow-up During Study



Monthly clinical disease activity (Mayo clinical score) MTX •PBO Oren R et al. Gastroenterology 1996

Methotrexate in UC

34 UC patients receiving treatment with PDN
Randomly assigned (2:2:1) to additionally receive, orally (30 weeks):
6-MP [1.5 mg/kg/day] vs. MTX [15 mg/week] vs. 5-ASA [3 g/day]



Spanish Multicentric Study on Clinical Use and Efficacy of MTX in UC

- **AIM:** To evaluate the efficacy and safety of MTX in UC patients.
- PATIENTS AND METHODS: 40 patients (70% steroid-dependency, 27% steroid refractoriness)
 Therapeutic success was defined as the absence of UC-related symptoms, steroid withdrawal and no requirement of rescue therapies within the first 6 months after starting MTX

• **RESULTS**:

- Previously treated with Thiopurines 87,5%
- Median dose for induction 25mg/wk parenterally
- 45% met criteria for therapeutic success
- Cumulative probability of maintaining **steroid-free** clinical **remission**
 - 60% (6 months), 48% (12 months), 35% (24 months) after starting MTX
- 27.5% experienced adverse events (MTX discontinuation in only 8)
- **CONCLUSIONS:** MTX appears to be **effective to maintain clinical remission in UC** (at least in the short-term) with an acceptable safety profile.

Controlled, Randomised, Double-Blind, Multicenter Study, Comparing **Methotrexate vs Placebo** in Steroid-Dependent UC (METEOR)

- **PHASE II** | Multicenter, **randomized**, double-**blind** study
- **INCLUSION** CRITERIA: Steroid-dependent ulcerative colitis
- **OBJECTIVES**: To show superiority of MTX vs PBO in inducing steroid-free remission in steroid-dependent UC
- **STUDY TREATMENTS**: **MTX 25 mg i.m./week** vs PBO 1 i.m./week
- **NUMBER** of patients: 55 patients in each group, i.e. a total of 110 patients
- EVALUATION CRITERIA: Remission without steroids at 16 and 24 weeks of ttx


A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis

• **BACKGROUND & AIMS:** To evaluate the efficacy of granulocyte/monocyte apheresis in patients with active moderate-to-severe UC

• METHODS:

- Randomized, double-blind, sham-controlled trial
- Community-based and tertiary care centers.
- Granulocyte/monocyte apheresis (Adacolumn Apheresis System) vs. sham apheresis
- 2:1 ratio for 9 weeks of treatment
- North American pivotal study (N = 168)
- Smaller study of identical design conducted in Europe and Japan (N = 47)


A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis



CONCLUSIONS: granulocyte/monocyte apheresis was well tolerated but **did not demonstrate efficacy** for induction of clinical remission or response in patients with moderate-to-severe UC.

Sands BE et al. Gastroenterology 2008

Anti-TNFs: High Rates of Loss of Response




Hanauer et al., Lancet 2002

Colombel JF et al., Gastroenterology 2007

Factors Affecting the PK of TNF-antagonists

	IMPACT on PK
Presence of ADAs	Decreases serum [mAbs]
	Three fold-increased clearance
	Worse clinical outcomes
Concomitant use of IS	Reduces ADAs
	Increases serum [mAbs]
	Decreases mAbs clearance
	Better clinical outcomes
High Baseline [TNF-α]	May decrease [mAbs] by increasing clearance
Low Albumin	Increases clearance
	Worse clinical outcomes
High Baseline CRP	Increases clearance
Body size	High BMI may increase clearance
Gender	Males have higher clearance


Proportions of Patients with Ulcerative Colitis Achieving Efficacy Endpoints by Serum Infliximab Concentrations (ACT1/ACT2)




Reinisch W, et al., Digestive Disease Week 2012; Abstract # 566

Exposure-Efficacy Relationship for Adalimumab during Induction Phase of Treatment of Patients with Moderate to Severe UC

• Aim: to characterize the relationship between trough [ADA] and clinical remission and response per Full Mayo Score (n=258) at induction (160-80 mg)






Exposure-Efficacy Relationship for Response at week 8

Exposure-Efficacy Relationship for Remission at week 8 Assessment of Adalimumab Dose Selection for Adult UC using Exposure-Response Analysis

- Higher wk 8 trough [adalimumab] are associated with:
 (1) greater % patients achieving clinical remission at week 8
 (2) increased duration of clinical remission
- Given the modest effect size of ADA for induction of remission (ADA 16.5% vs. PBO 9.3%) a higher dose for the induction of remission may provide greater benefit to UC patients




Factors Affecting the PK of TNF-antagonists

	IMPACT on PK	
Presence of ADAs	Decreases serum [mAbs] Three fold-increased clearance Worse clinical outcomes	
Concomitant use of IS	Reduces ADAs Increases serum [mAbs] Decreases mAbs clearance Better clinical outcomes	
High Baseline [TNF-α]	May decrease [mAbs] by increasing clearance	
Low Albumin	Increases clearance Worse clinical outcomes	
High Baseline CRP	Increases clearance	
Body size	High BMI may increase clearance	
Gender	Males have higher clearance	

Population Kinetics of IFX from ACT 1 and ACT 2

 Albumin concentration was <u>inversely</u> proportional to the clearance of infliximab




Fasanmade et al. Eu J Clin Pharmacol 2009


Serum Albumin Concentration Predicts PK and Clinical Response in Patients with Ulcerative Colitis

Higher SAC - Higher [IFX],

lower CL and longer T_{1/2}



Patients with Albumin below normal had a lower response rate




Pharmacokinetics of Adalimumab in Adult Patients with Moderately to Severely Active Ulcerative Colitis


Aim: to characterize the PK of ADA in moderate-to-severe UC

- Randomized, double blind, placebo-controlled, 52-week study
- Serum [ADA] trough at Weeks 0, 2, 4, 8, 32 and 52
- Serum Anti-Adalimumab Antibody (AAA) at Weeks 0, 8, 32 and 52
- Effect of Baseline covariates on ADA PK
- Only body weight and plasma albumin were found to be statistically significant covariates; (explained 4.9% and 3.7% of the total PK variability, respectively)
- A combination of multiple covariates (body weight, albumin, age, sex, CRP and concomitant IMM) explain 13% of the total variability in PK

Pharmacokinetics of Adalimumab in Adult Patients with Moderately to Severely Active Ulcerative Colitis

Effect of Body weight, Albumin and CRP on Adalimumab Clearance





Mean ADA Clearance increased slightly with

- increasing body weight and CRP
- decreased with increasing albumin

(substantial overlap between quartiles)

Future

\diamond The light on thehorizon...?

- ♦ Budesonide MMX
- ♦ Golimumab (anti-TNF)
- ♦ Tofacitinib (Jak inhibitor)
- Vedolizumab (α4β7)




Budesonide MMX

- Releases budesonide throughout colon
- Enteric coat dissolves at pH 7
- Proposed indication: induction of remission of active mild-to-moderate UC






90% metabolism in the liver



10 % systemic

Once-daily budesonide MMX in active, mild-tomoderate UC: results from the randomised CORE II trial


> Primary endpoint: combined **clinical and endoscopic** remission at week 8 (n=410)



Subcutaneous Golimumab Induces Clinical Response and Remission in Moderate-to-Severe UC


- Phase III double-blind randomized
- Two phases
 - Induction (n=774; efficacy & safety week 6)
 - PBO
 - Golimumab 400, 200 mg/eow
 - Golimumab 200, 100 mg/eow
 - Maintenance (n=464; wk 52)
 - PBO
 - Golimumab (50 mg or 100 mg)/4 weeks

Clinical Remission and Mucosal Healing at both Week 30 and 54: Randomized Patients in Clinical Response to Golimumab Induction



Tofacitinib

- Small molecule (oral)
- JAK kinase inhibitor
 - Affinity for JAK 1 and 3
 - Inhibits cytokine signaling
- Metabolized by liver (CYP3A4)
- Phase 2 clinical trial suggests efficacy in UC




Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

- Phase 2 placebo RCT (n=194)
- Mayo 6-12 (endoscopy ≥ 2) | 40% IMM failure | 30% prior anti-TNF
- Treatment arms:
 - PBO (n=48)
 - Tofacitinib 0,5 mg (n=31)
 - Tofacitinib 3 mg (n=33)
 - Tofacitinib 10 mg (n=33)
 - Tofacitinib 15 mg (n=33)
- Short term trial 2 months

Tofacitinib


Clinical Remission

Endoscopic Remission



Vedolizumab


- Humanized IgG 1 monoclonal antibody to $\alpha 4\beta 7$ integrin
- Modulates gut, but NOT
 brain lymphocyte trafficking
- Less risk of PML compared to natalizumab



Vedolizumab as Induction and Maintenance Therapy for UC

- Combination PBO controlled and open-label trial
 - 374 patients vedolizumab or placebo
 - 521 patients open label vedolizumab
- Active UC (Mayo 6-12, endoscopy subscore 2)
- Induction two doses week 0 and 2
- Maintenance: responders continued on active drug, or randomized to PBO

Vedolizumab - Results



Week 52 (remission in the responders)

Final Remarks

- Chronic unremitting UC is relatively frequent
- Optimization of available therapies is crucial to achieve better outcomes
- With regard to anti-TNF therapies, a better knowledge of their PK profile is needed
- In the forthcoming years new therapies will be available